

Keynote Session

A. Peterle



A. Peterle

In his Keynote session, Mr Peterle will introduce to us his view on the pharmacists' responsibilities within a multi-professional healthcare team as well as the importance of a good collaboration with patients themselves. He will address the issue of inequality in access to appropriate cancer treatment and prevention in

Europe. As an active promoter of the fight against cancer and a cancer survivor himself, Mr Peterle will stress the importance of cancer patients taking an active role in their treatment. In his lecture he will also inform us about the latest activities on the topic of cancer within the European Parliament.

Copyright:
ESOP
Veritaskai 6
21079 Hamburg
Germany

Editor: Kleio Bourika, Eda Gedikoglu

The greeting of the patron V. Andriukaitis for the ECOP 4:

<http://ec.europa.eu/avservices/preview.cfm?ref=1162205&videolang=EN>



Debate - Clinical/Practical Safe Compounding

Y. Cass

25 years ago Mr. Cass was appointed to chair of the selected committee on safe handling of cytotoxic drugs in Israel. Since then, he continues to be at the forefront of the movement to regulate safe use of cytotoxics in Israel. His many scientific writings include chapters for prestigious "Cytotoxic Handbook".

His presentation will include:

- Introduction of chemotherapy into clinical practice.

- Risks of occupational exposure to hazardous drugs without protective measures.

- History of attempts to reduce exposure by using good-handling practice guidelines and protective measures.

- The so called "Hierarchical System", NIOSH alert and their recommendations on Closed System Transfer Devices (CSTD's)

as an essential tool in the safe handling armamentarium.

- Misgivings on relying on laminar flow hoods and isolators to protect personnel handling cytotoxics.

- Other international guidelines and their viewpoint on the use of CSTD's.

- Proofs that CSTDs reduce exposure to chemotherapy drugs in their reconstitution and administration.



ECOP2018 - Scientific Programme Overview

Thursday 25 October 2018		Friday 26 October 2018			Saturday 27 October 2018	
Room 200	Room GH	Auditorium 450	Room 200	Room GH	Auditorium 450	Room 200
MASHA Training (Closed Session) E. Korczowska (PL) K. Meier (DE) B. Tans (BE) 08:30 - 11:30	Workshop: Pharmacovigilance: How to Classify Severity and How to Establish Causality M. Genc (SI) 09:30 - 10:30	Workshop: Love and Sexuality of Oncological Patients V. Pavlica (HR) G. Arbanas (HR) O. Spasovska (MK) J. Vrbanec (HR) 09:30 - 10:30	Workshop: Value based Pharmacy: Developing Qualitative Parameters for Drug and Public Procurement M. Skalin (HR) E. Javor (HR) 08:30 - 09:30	Workshop: The Role of the Oncology Pharmacist in Clinical Trials C. Bardin (FR) E. Korczowska (PL) 08:30 - 09:30	Keynote Session B. J. Venhuis (NL) F. F. Conze (IT) 08:30 - 10:00	
Industry Sponsored Mini Symposium 10:30 - 11:40	Industry Sponsored Mini Symposium 10:30 - 11:40	Keynote Lecture New Drugs in Oncology M. Skowronski (CZ) 09:30 - 10:30	Keynote Lecture New Drugs in Oncology M. Skowronski (CZ) 09:30 - 10:30	Keynote Lecture New Drugs in Oncology M. Skowronski (CZ) 09:30 - 10:30		
Industry Sponsored Mini Symposium 11:50 - 13:00	The Future of Oncology Pharmacy 2025	Joint ESOP - SIOG Clinical Symposium Genetic Oncology S. O'Hanlon (IE) L. Mouray (FR) 11:00 - 12:00	ESOP - ESOP Joint Symposium (Practical) A. Bonak (TK) M. Agaro (CH) 11:00 - 12:00	Symposium Cost Management of Cancer Care A. Astier (FR) M. Dahan (FR) 11:00 - 12:00	ECCO - ESOP Joint Symposium Essential Requirements for Quality Cancer Care M. Skalin (HR) P. Harari (SE) 10:00 - 11:30	Symposium (Practical) J. Hendrix (NL) I. Netkova (CZ) 10:00 - 11:30
		Clinical Symposium Prevention and Management of Side Effects P. Dür (DE) N. Varga Marquies (PT) 12:00 - 13:00	New Horizons Practical: Automation and Robotics in Oncology Pharmacy E. B. Lundie (NO) J. Wernke-Rösche (DE) 12:00 - 13:00	Round Table Discussion: Pharmacoeconomic Evaluation of Oncology Drugs E. Tsakris (GR) A. Astier (FR) E. Pizzo (UK) 12:00 - 13:00	Coffee Break / Poster Viewing / Poster Spotlight / Exhibition 11:30 - 12:30	Clinical - Interactive N. van Erp (Netherlands) S. Gilbeud (FR) (incl. 2 Proffered Papers) 12:30 - 13:45
						Special Session Patient Perspectives I. Banks (UK) R. York (UK) 12:30 - 13:30
		Lunch (Fingerfood) 13:00 - 14:00	Lunch Break / Poster Viewing / Exhibition / Networking (Exhibition Hall) 13:00 - 14:00	Lunch Break / Poster Viewing / Exhibition / Networking (Exhibition Hall) 13:00 - 14:00		
Clinical Symposium: Immunotherapy W. Weichert (DE) M. Boers-Sonderen (NL) E. Moreno Martinez (ES) 14:00 - 15:00	Debate - Clinical/Practical Safe Compounding O. Breakeis (NL) Y. Cass (IL) 14:00 - 15:00	Industry Sponsored Symposium 14:00 - 15:30	Industry Sponsored Symposium 14:00 - 15:30	Industry Sponsored Symposium 14:00 - 15:30		
	New Horizons Clinical Liquid Biopsies and Volatile Markers in Cancer H. Schwarzenbach (DE) L. Koniczka (PL) 15:00 - 16:00					
	Coffee Break (Exhibition Hall) 16:00 - 16:15					
Opening 16:15 - 16:45 B. Assah (representative from the city of Nantes) K. Meier E. Grol C. Bardin						
Keynote Session A. Peterle (SI) I. Klingmann (BE) 16:45 - 18:00						
	Exhibitor's Welcome Reception (Mezzanine) 18:00 - 19:30					
		Clinical - Interactive Supportive Care I. Netkova (CZ) M. Agaro (CH) (incl. 3 Proffered Papers) 16:30 - 18:00	Practical - Interactive Drug Stability J. Vigueron (FR) E. de Haan (FR) (incl. 3 Proffered Papers) 16:30 - 18:00	SIOPE - ESOP Joint Symposium (Practical) Dose Banding J.S. Veal (UK) S. Hossny Kamal (EG) 16:30 - 18:00	Closing Remarks, Conference Highlights and Awards 13:45 - 14:00	

Last updated: 22.10.2018

The Future of Oncology Pharmacy 2025

R. Gonce

The progress and development in oncology is going on rapidly and oncology pharmacists keep pace with it. We should define the topics we are going to address in following years. A survey among the members and delegates returned ideas that should be implemented in our plans. These include safety issues, education,

co-operation, novel therapies, etc. The goals that are waiting for us are going to be resolved on many levels.

From ESOP, through national organizations, to individual oncology pharmacists, everybody is going to discuss with their counterparts and peers,

such as authorities, societies, healthcare professionals, community pharmacists, etc., any common or overlapping interests in the afore mentioned fields. Only in this way we will be able to promote our goals and continue improving our daily practice.

New Horizons Clinical Liquid Biopsies and Volatile Markers in Cancer

H. Schwarzenbach

The term "liquid biopsy" was originally defined as "A test made on a blood sample to determine the presence of either circulating cancer cells (CTCs) or cell-free DNA fragments (cfDNA) from a tumor circulating in the blood".

Its importance lays in the minimally invasive approach that can be repeated on the same patient at frequent intervals. A specific feature of liquid biopsy is that it can overcome the interference of tumor heterogeneity and

reflect the general information of primary tumor and metastasis. Although the initial definition limits the term to CTCs and cfDNA in blood, liquid biopsy comprises a range of further components that are released by cell apoptosis and necrosis, or actively by exosomes into various body fluids. The most studied volatile markers are

- CTCs,
- cfDNA,
- microRNAs (miRNAs) and
- exosomes in blood.

Analyses of these volatile markers in liquid biopsies offer a range of information on tumor dynamics during treatment and disease progression, and provide new horizons in the concept of precision medicine and perspectives of patient-tailored therapies.

Quick Info

Workshop:

Love and Sexuality of Oncological Patients

V.Pavlica (HR), G. Arbanas (HR), O. Spasovska (MK) J. Vrbanec (HR)

09.30 – 10.30 Room GH

Highlights in Nantes

Land of the bold

At a time of stiff competitions between regions, Nantes Saint-Nazaire is not just surviving but thriving...

Economic dynamism, accessibility, quality of life, a protected environment, culture and creativity: in all of these areas and more, Nantes Saint-Nazaire offers an embarrassment of riches.

An XXL Metropolis

Take two examples. The first: a 12 metre-tall statue of an elephant sculpted from wood and steel, a popular perch from which to discover Nantes. The second: the launch of the world's largest cruise ship, made in Saint-Nazaire and capturing the headlines of media outlets all over the world. Two 'XXL' images which embody the new dimension which Nantes Saint-Nazaire has entered. The former as a symbol of the dynamic spirit which reigns in the metro area, where the cultural and creative sectors are major growth drivers. The latter as an emblem of the boundless possibilities of naval construction in the Loire estuary, and more broadly the dynamism of a local industrial sector powered by high technology.

Intelligence Meets Innovation

The economic dynamism of Nantes Saint-Nazaire is powered by a number of centres of excellence, with great potential for future growth. The metropolis is home to some 2,200 researchers and 200 laboratories spread across companies, universities and specialist schools, in a region with a particularly strong academic community, including over 50,000 students. Strong numbers which go some way to explaining the atmosphere of creativity and shared innovation which prevails in the metro area. The western tip of the Île de Nantes has been transformed. The former naval shipyard has metamorphosed into a hub of culture and creativity. The large-scale public art project known as Les Machines de l'Île provides an original showcase for Nantes' creative spirit.

A Commitment to Culture

Nantes, the sixth largest city in France and European Green Capital in 2013, has made a conscious decision to focus on culture to reinforce its image and appeal, in synergy with the city's entrepreneurial and industrial temperament. The many high-profile artistic events which take place throughout Nantes are an intrinsic part of the city's identity, and have played a major role in redefining the inner city.




Cité des Congrès (Copyright, Jean-Dominique Billaud)



Hall XXL (Copyright, Gaël Arnaud)



Elephant (Copyright, Gaël Arnaud)



European Conference of Oncology Pharmacy - Thursday, 25th October 2018



Klaus Meier

Unity in Diversity

The world seems to be upside down. Everything that was right and normal, appears in a gray light. Selfishness and protectionism seem to become the models of the present, born of the deep-rooted fear of losing everything and being over-privileged by others.

The world society has built in the last 70 years common laws to curb egoism and its effects for all. The fear to lose arises mostly from the fear of the other and the unknown. As you know, the other thing in this world is created by this world. No matter what skin color people have, they remain people with shared values and feelings. Love and friendship, cooperation and sense of discovery are the driving forces we can take from the signs and messages of our ancestors.

The ability to communicate is given to us through our organs, the eyes, the skin, the ears and the mouth. The more we use them, the less alien we are to the previously unknown, and the more we gain the certainty that common goals are possible.

More than 20 years ago, the first of us agreed to a motto: "Unity in diversity". In the meantime, the few members of that time have become many. Not only in the countries of the European Union or neighboring countries, but in all parts of the world, this goal is supported by nearly 4,000 members of our society every day.

As pharmacists, we have prescribed ourselves to the patient. Learning, exchanging and communicating promotes the well-being of patients all over the world. Nearly pharmacists from a third of all countries in the world meet here in Nantes. The world should hear about our will to change and to support.



Mirjam Crul

Editorial



On the occasion of the 4th European Congress of Oncology Practitioners, all the attendees will have the chance to get the ECOP daily newsletter. The newsletters will include highlights of the day, tips for a visit in the amazing city of Nantes, photos of the previous day and results from questionnaires, answered by the attendees. I wish you much fun while reading the ECOP Daily Newsletters and DON'T forget to take all the three issues with you, back home.

In the future, you will be happy to recall the memories from those famous days in Nantes.

Enjoy!

Yours,
Kleio Bourika

Workshop:

Quick Info

Pharmacovigilance: How to Classify Severity and How to Establish Causality

M. Sonc (SL)

09.30 – 10.30

Room 200